Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.35 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30298622 | 1.00 | MPI (0.44) | MPIAPLNRNNMTKDM4EP2RY6 | |
| Hydrochloric Acid SCHEMBL10418405 | 0.98 | MPI (0.43) | MPIAPLNRNNMTKDM4EP2RY6 | |
| SCHEMBL11710048 | 0.85 | RAB9A (0.42) | APLNRKDM4EMIFMEN1KMT2A | |
| SCHEMBL11710623 | 0.84 | MAPT (0.45) | APLNRP2RY6MIFMEN1KMT2A | |
| SCHEMBL856393 | 0.81 | MPI (0.44) | MPINNMTKDM4ECYP2A6MKNK1 | |
| SCHEMBL11712035 | 0.81 | MIF (0.46) | APLNRMIFMEN1KMT2A | |
| SCHEMBL11709850 | 0.81 | NPC1 (0.52) | KDM4EP2RY6MIFMEN1KMT2A | |
| SCHEMBL11709823 | 0.81 | ALDH1A1 (0.42) | P2RY6MIF | |
| SCHEMBL11707937 | 0.79 | MEN1 (0.58) | APLNRKDM4EMEN1KMT2A | |
| SCHEMBL11707857 | 0.78 | KDM4E (0.51) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| CN-113149961-B | Azabicyclo-substituted triazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-111902406-B | Medicinal salt and crystal form of aza-bicyclyl substituted triazole derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20210040073-A1 | AZABICYCLO-SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND APPLICATION OF SAME IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC | 2006-07-20 | — | — | US | disclosed |
| EP-1200430-A4 | THIOUREA AND ISOTHIOUREA DERIVATIVES FOR INHIBITING RAS-TRANSFORMED CELL GROWTH | YUHAN CORP LTD (KR) | 2003-01-22 | — | — | EP | disclosed |
| EP-1200430-A1 | THIOUREA AND ISOTHIOUREA DERIVATIVES FOR INHIBITING RAS-TRANSFORMED CELL GROWTH | YUHAN CORPORATION, LTD. (KR) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009128-A1 | THIOUREA AND ISOTHIOUREA DERIVATIVES FOR INHIBITING RAS-TRANSFORMED CELL GROWTH | YUHAN CORPORATION (KR) | 2001-02-08 | — | — | WO | disclosed |
| WO-1999012912-A1 | THIOUREA DERIVATIVES OR NON-TOXIC SALTS THEREOF FOR INHIBITNG RAS-TRANSFORMED CELL GROWTH | YUHAN CORPORATION (KR) | 1999-03-18 | — | — | WO | disclosed |
| EP-0470006-B1 | Thiourea derivatives and antimicrobial agent and antiulcer agent containing the same | TERUMO CORP (JP) | 1994-12-14 | — | — | EP | disclosed |
| US-5190961-A | Bactericides | TERUMO KABUSHIKI KAISHA (JP) | 1993-03-02 | — | — | US | disclosed |
| EP-0470006-A1 | Thiourea derivatives and antimicrobial agent and antiulcer agent containing the same | TERUMO KABUSHIKI KAISHA (JP) | 1992-02-05 | — | — | EP | disclosed |
| EP-0321368-A1 | Heterocyclic N-carbamoyl, N-thiocarbamoyl or N-amidino-aminomalonyl or -aminosuccinyl amide derivatives as sweetening agents | NOFRE, Claude (FR) | 1989-06-21 | — | — | EP | disclosed |
| US-4001254-A | ISOTHIOCYANOPYRIDINE DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | MPI 3758/4885APLNR 3496/4885NNMT 2677/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | MPI 3758/4885APLNR 3496/4885NNMT 2677/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | MPI 3758/4885APLNR 3496/4885NNMT 2677/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MPI 1665/4885APLNR 4382/4885NNMT 2839/4885 |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | OXTR, AVPR1B, GNRHR | MPI 4222/4885APLNR 1165/4885NNMT 2051/4885 |
| US-20210040073-A1 | AZABICYCLO-SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND APPLICATION OF SAME IN MEDICINE | OXTR, CRH, MC2R | MPI 3638/4885APLNR 1892/4885NNMT 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.